Screening for Cognitive Impairment Associated with Chemotherapy for Breast Cancer

Diane F. Morean*, Leora R. Cherney

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


At least 20 % of women treated with chemotherapy for breast cancer experience some form of cognitive decline. Recent recommendations call for clinicians to screen cognitive abilities. Screening of factors that can contribute to cognitive impairment is also currently recommended. We describe a battery of free, online, self-report surveys that would take approximately 30 min to complete in the context of an overall functional assessment of wellness. Key physical characteristics to be screened include fatigue and insomnia. Significant psychological characteristics include distress, depression, and anxiety. Fundamental social characteristics include basic needs, workplace issues, and interpersonal well-being. Systematic screening that could be completed in the clinic waiting room or during chemotherapy infusion is an important first step towards more holistic patient care that addresses cognitive side effects, just as physical side effects of treatment are routinely addressed.

Original languageEnglish (US)
Pages (from-to)151-157
Number of pages7
JournalCurrent Breast Cancer Reports
Issue number3
StatePublished - Sep 1 2016


  • Adjuvant chemotherapy
  • Adverse effects
  • Anxiety
  • Brain
  • Breast neoplasms
  • Cognition
  • Cognition disorders
  • Depression
  • Executive function
  • Fatigue
  • Memory
  • Psychological stress
  • Quality of life
  • Surveys and questionnaires
  • Survivors

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Screening for Cognitive Impairment Associated with Chemotherapy for Breast Cancer'. Together they form a unique fingerprint.

Cite this